Cargando…
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
In the present editorial we describe the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We focus on the major breakthroughs we have been witnessing in this context, from the introduction of crizotinib...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioExcel Publishing Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044318/ https://www.ncbi.nlm.nih.gov/pubmed/30023004 http://dx.doi.org/10.7573/dic.212537 |